Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2019 from OUS - Department of Tumor Biology

74 publications found

Abrahamsson H, Porojnicu AC, Lindstrøm JC, Dueland S, Flatmark K, Hole KH, Seierstad T, Moan J, Redalen KR, Meltzer S, Ree AH (2019)
High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer
BMC Cancer, 19 (1), 488
DOI 10.1186/s12885-019-5724-z, PubMed 31122213

Aghayan DL, Fretland ÅA, Kazaryan AM, Sahakyan MA, Dagenborg VJ, Bjørnbeth BA, Flatmark K, Kristiansen R, Edwin B (2019)
Laparoscopic versus open liver resection in the posterosuperior segments: a sub-group analysis from the OSLO-COMET randomized controlled trial
HPB (Oxford), 21 (11), 1485-1490
DOI 10.1016/j.hpb.2019.03.358, PubMed 30962136

Andersson Y, Inderberg EM, Kvalheim G, Herud TM, Engebraaten O, Flatmark K, Dueland S, Fodstad Ø (2019)
Immune stimulatory effect of anti-EpCAM immunotoxin - improved overall survival of metastatic colorectal cancer patients
Acta Oncol, 59 (4), 404-409
DOI 10.1080/0284186X.2019.1704864, PubMed 31876430

Bains SJ, Abrahamsson H, Flatmark K, Dueland S, Hole KH, Seierstad T, Redalen KR, Meltzer S, Ree AH (2019)
Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer
Cancer Immunol Immunother, 69 (3), 355-364
DOI 10.1007/s00262-019-02458-x, PubMed 31893287

Barkovskaya A, Seip K, Hilmarsdottir B, Maelandsmo GM, Moestue SA, Itkonen HM (2019)
O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes
Sci Rep, 9 (1), 5670
DOI 10.1038/s41598-019-42153-6, PubMed 30952976

Briem E, Ingthorsson S, Traustadottir GA, Hilmarsdottir B, Gudjonsson T (2019)
Application of the D492 Cell Lines to Explore Breast Morphogenesis, EMT and Cancer Progression in 3D Culture
J Mammary Gland Biol Neoplasia, 24 (2), 139-147
DOI 10.1007/s10911-018-09424-w, PubMed 30684066

Brudvik KW, Jones RP, Giuliante F, Shindoh J, Passot G, Chung MH, Song J, Li L, Dagenborg VJ, Fretland ÅA, Røsok B, De Rose AM, Ardito F, Edwin B, Panettieri E, Larocca LM, Yamashita S, Conrad C, Aloia TA, Poston GJ, Bjørnbeth BA, Vauthey JN (2019)
RAS Mutation Clinical Risk Score to Predict Survival After Resection of Colorectal Liver Metastases
Ann Surg, 269 (1), 120-126
DOI 10.1097/SLA.0000000000002319, PubMed 28549012

Braadland PR, Ramberg H, Grytli HH, Urbanucci A, Nielsen HK, Guldvik IJ, Engedal A, Ketola K, Wang W, Svindland A, Mills IG, Bjartell A, Taskén KA (2019)
The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells
Mol Cancer Res, 17 (11), 2154-2168
DOI 10.1158/1541-7786.MCR-18-0605, PubMed 31395667

Braadland PR, Urbanucci A (2019)
Chromatin reprogramming as an adaptation mechanism in advanced prostate cancer
Endocr Relat Cancer, 26 (4), R211-R235
DOI 10.1530/ERC-18-0579, PubMed 30844748

Calvete J, Larrinaga G, Errarte P, Martín AM, Dotor A, Esquinas C, Nunes-Xavier CE, Pulido R, López JI, Angulo JC (2019)
The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder
Hum Pathol, 91, 61-68
DOI 10.1016/j.humpath.2019.07.002, PubMed 31279874

Camilio KA, Wang MY, Mauseth B, Waagene S, Kvalheim G, Rekdal Ø, Sveinbjørnsson B, Mælandsmo GM (2019)
Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
Breast Cancer Res, 21 (1), 9
DOI 10.1186/s13058-018-1092-x, PubMed 30670061

Crosbie EJ, Ryan NAJ, Arends MJ, Bosse T, Burn J, Cornes JM, Crawford R, Eccles D, Frayling IM, Ghaem-Maghami S, Hampel H, Kauff ND, Kitchener HC, Kitson SJ, Manchanda R, McMahon RFT, Monahan KJ, Menon U, Møller P, Möslein G, Rosenthal A, Sasieni P, Seif MW, Singh N, Skarrott P et al. (2019)
The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome
Genet Med, 21 (10), 2390-2400
DOI 10.1038/s41436-019-0489-y, PubMed 30918358

Debik J, Euceda LR, Lundgren S, Gythfeldt HVL, Garred Ø, Borgen E, Engebraaten O, Bathen TF, Giskeødegård GF (2019)
Assessing Treatment Response and Prognosis by Serum and Tissue Metabolomics in Breast Cancer Patients
J Proteome Res, 18 (10), 3649-3660
DOI 10.1021/acs.jproteome.9b00316, PubMed 31483662

Della Valle A, Rossi BM, Palmero EI, Antelo M, Vaccaro CA, López-Kostner F, Alvarez K, Cruz-Correa M, Bruno LI, Forones NM, Mindiola JAR, Buleje J, Spirandelli F, Bohorquez M, Cock-Rada AM, Sullcahuaman Y, Nascimento I, Abe-Sandes K, Lino-Silva LS, Petracchi F, Mampel A, Rodriguez Y, Rossi NT, Yañez CB, Rubio C et al. (2019)
A snapshot of current genetic testing practice in Lynch syndrome: The results of a representative survey of 33 Latin American existing centres/registries
Eur J Cancer, 119, 112-121
DOI 10.1016/j.ejca.2019.07.017, PubMed 31442815

Dominguez-Valentin M, Nakken S, Tubeuf H, Vodak D, Ekstrøm PO, Nissen AM, Morak M, Holinski-Feder E, Holth A, Capella G, Davidson B, Evans DG, Martins A, Møller P, Hovig E (2019)
Results of multigene panel testing in familial cancer cases without genetic cause demonstrated by single gene testing
Sci Rep, 9 (1), 18555
DOI 10.1038/s41598-019-54517-z, PubMed 31811167

Dominguez-Valentin M, Sampson JR, Seppälä TT, Ten Broeke SW, Plazzer JP, Nakken S, Engel C, Aretz S, Jenkins MA, Sunde L, Bernstein I, Capella G, Balaguer F, Thomas H, Evans DG, Burn J, Greenblatt M, Hovig E, de Vos Tot Nederveen Cappel WH, Sijmons RH, Bertario L, Tibiletti MG, Cavestro GM, Lindblom A, Della Valle A et al. (2019)
Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database
Genet Med, 22 (1), 15-25
DOI 10.1038/s41436-019-0596-9, PubMed 31337882

Dominguez-Valentin M, Seppälä TT, Sampson JR, Macrae F, Winship I, Evans DG, Scott RJ, Burn J, Möslein G, Bernstein I, Pylvänäinen K, Renkonen-Sinisalo L, Lepistö A, Lindblom A, Plazzer JP, Tjandra D, Thomas H, Green K, Lalloo F, Crosbie EJ, Hill J, Capella G, Pineda M, Navarro M, Vidal JB et al. (2019)
Survival by colon cancer stage and screening interval in Lynch syndrome: a prospective Lynch syndrome database report
Hered Cancer Clin Pract, 17, 28
DOI 10.1186/s13053-019-0127-3, PubMed 31636762

Dörk T, Peterlongo P, Mannermaa A, Bolla MK, Wang Q, Dennis J, Ahearn T, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Augustinsson A, Freeman LEB, Beckmann MW, Beeghly-Fadiel A, Behrens S, Bermisheva M, Blomqvist C, Bogdanova NV, Bojesen SE, Brauch H, Brenner H, Burwinkel B, Canzian F, Chan TL et al. (2019)
Two truncating variants in FANCC and breast cancer risk
Sci Rep, 9 (1), 12524
DOI 10.1038/s41598-019-48804-y, PubMed 31467304

Escala-Garcia M, Guo Q, Dörk T, Canisius S, Keeman R, Dennis J, Beesley J, Lecarpentier J, Bolla MK, Wang Q, Abraham J, Andrulis IL, Anton-Culver H, Arndt V, Auer PL, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Boeckx B, Bojesen SE, Bonanni B, Børresen-Dale AL et al. (2019)
Genome-wide association study of germline variants and breast cancer-specific mortality
Br J Cancer, 120 (6), 647-657
DOI 10.1038/s41416-019-0393-x, PubMed 30787463

Flem-Karlsen K, McFadden E, Omar N, Haugen MH, Øy GF, Ryder T, Gullestad HP, Hermann R, Mælandsmo GM, Flørenes VA (2019)
Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma
Mol Cancer Ther, 19 (3), 895-905
DOI 10.1158/1535-7163.MCT-19-0290, PubMed 31871265

Flem-Karlsen K, Tekle C, Øyjord T, Flørenes VA, Mælandsmo GM, Fodstad Ø, Nunes-Xavier CE (2019)
p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance
Sci Rep, 9 (1), 5839
DOI 10.1038/s41598-019-42303-w, PubMed 30967582

Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM (2019)
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
Transl Oncol, 12 (7), 951-958
DOI 10.1016/j.tranon.2019.04.001, PubMed 31096111

Forthun RB, Hovland R, Schuster C, Puntervoll H, Brodal HP, Namløs HM, Aasheim LB, Meza-Zepeda LA, Gjertsen BT, Knappskog S, Straume O (2019)
ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab
Sci Rep, 9 (1), 17471
DOI 10.1038/s41598-019-53917-5, PubMed 31767937

Fretland ÅA, Dagenborg VJ, Waaler Bjørnelv GM, Aghayan DL, Kazaryan AM, Barkhatov L, Kristiansen R, Fagerland MW, Edwin B, Andersen MH (2019)
Quality of life from a randomized trial of laparoscopic or open liver resection for colorectal liver metastases
Br J Surg, 106 (10), 1372-1380
DOI 10.1002/bjs.11227, PubMed 31322735

Frøysnes IS, Andersson Y, Larsen SG, Davidson B, Øien JT, Julsrud L, Fodstad Ø, Dueland S, Flatmark K (2019)
ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis
Eur J Surg Oncol (in press)
DOI 10.1016/j.ejso.2019.04.014, PubMed 31036394

Goodridge JP, Jacobs B, Saetersmoen ML, Clement D, Hammer Q, Clancy T, Skarpen E, Brech A, Landskron J, Grimm C, Pfefferle A, Meza-Zepeda L, Lorenz S, Wiiger MT, Louch WE, Ask EH, Liu LL, Oei VYS, Kjällquist U, Linnarsson S, Patel S, Taskén K, Stenmark H, Malmberg KJ (2019)
Remodeling of secretory lysosomes during education tunes functional potential in NK cells
Nat Commun, 10 (1), 514
DOI 10.1038/s41467-019-08384-x, PubMed 30705279

Grinde MT, Hilmarsdottir B, Tunset HM, Henriksen IM, Kim J, Haugen MH, Rye MB, Mælandsmo GM, Moestue SA (2019)
Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer
Breast Cancer Res, 21 (1), 61
DOI 10.1186/s13058-019-1141-0, PubMed 31088535

Handle F, Prekovic S, Helsen C, Van den Broeck T, Smeets E, Moris L, Eerlings R, Kharraz SE, Urbanucci A, Mills IG, Joniau S, Attard G, Claessens F (2019)
Drivers of AR indifferent anti-androgen resistance in prostate cancer cells
Sci Rep, 9 (1), 13786
DOI 10.1038/s41598-019-50220-1, PubMed 31551480

Hanes R, Munthe E, Grad I, Han J, Karlsen I, McCormack E, Meza-Zepeda LA, Stratford EW, Myklebost O (2019)
Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma
Cells, 8 (2)
DOI 10.3390/cells8020189, PubMed 30795553

Hansen EP, Fromm B, Andersen SD, Marcilla A, Andersen KL, Borup A, Williams AR, Jex AR, Gasser RB, Young ND, Hall RS, Stensballe A, Ovchinnikov V, Yan Y, Fredholm M, Thamsborg SM, Nejsum P (2019)
Exploration of extracellular vesicles from Ascaris suum provides evidence of parasite-host cross talk
J Extracell Vesicles, 8 (1), 1578116
DOI 10.1080/20013078.2019.1578116, PubMed 30815237

Hausken J, Fretland ÅA, Edwin B, Andersen MH, Dagenborg VJ, Bjørnelv GMW, Kristiansen R, Røysland K, Kvarstein G, Tønnessen TI (2019)
Intravenous Patient-controlled Analgesia Versus Thoracic Epidural Analgesia After Open Liver Surgery: A Prospective, Randomized, Controlled, Noninferiority Trial
Ann Surg, 270 (2), 193-199
DOI 10.1097/SLA.0000000000003209, PubMed 30676382

Hausott B, Förste A, Zach F, Mangger S, Haugsten EM, Klimaschewski L (2019)
Endocytosis and Transport of Growth Factor Receptors in Peripheral Axon Regeneration: Novel Lessons from Neurons Expressing Lysine-Deficient FGF Receptor Type 1 in vitro
Anat Rec (Hoboken), 302 (8), 1268-1275
DOI 10.1002/ar.24120, PubMed 30950230

Itkonen HM, Urbanucci A, Martin SE, Khan A, Mathelier A, Thiede B, Walker S, Mills IG (2019)
High OGT activity is essential for MYC-driven proliferation of prostate cancer cells
Theranostics, 9 (8), 2183-2197
DOI 10.7150/thno.30834, PubMed 31149037

Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred Ø, Boekel J, Sauer T, Zhao W, Nord S, Höglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF et al. (2019)
Breast cancer quantitative proteome and proteogenomic landscape
Nat Commun, 10 (1), 1600
DOI 10.1038/s41467-019-09018-y, PubMed 30962452

Juraleviciute M, Pozniak J, Nsengimana J, Harland M, Randerson-Moor J, Wernhoff P, Bassarova A, Øy GF, Trøen G, Flørenes VA, Bishop DT, Herlyn M, Newton-Bishop J, Slipicevic A (2019)
MX 2 is a novel regulator of cell cycle in melanoma cells
Pigment Cell Melanoma Res, 33 (3), 446-457
DOI 10.1111/pcmr.12837, PubMed 31660681

Kanduri C, Bock C, Gundersen S, Hovig E, Sandve GK (2019)
Colocalization analyses of genomic elements: approaches, recommendations and challenges
Bioinformatics, 35 (9), 1615-1624
DOI 10.1093/bioinformatics/bty835, PubMed 30307532

Kotsopoulos J, Lubinski J, Lynch HT, Tung N, Armel S, Senter L, Singer CF, Fruscio R, Couch F, Weitzel JN, Karlan B, Foulkes WD, Moller P, Eisen A, Ainsworth P, Neuhausen SL, Olopade O, Sun P, Gronwald J, Narod SA, Hereditary Breast Cancer Clinical Study Group (2019)
Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers
Breast Cancer Res Treat, 175 (2), 443-449
DOI 10.1007/s10549-019-05162-7, PubMed 30756284

Lai X, Geier OM, Fleischer T, Garred Ø, Borgen E, Funke SW, Kumar S, Rognes ME, Seierstad T, Børresen-Dale AL, Kristensen VN, Engebraaten O, Köhn-Luque A, Frigessi A (2019)
Toward Personalized Computer Simulation of Breast Cancer Treatment: A Multiscale Pharmacokinetic and Pharmacodynamic Model Informed by Multitype Patient Data
Cancer Res, 79 (16), 4293-4304
DOI 10.1158/0008-5472.CAN-18-1804, PubMed 31118201

Lien VT, Kristiansen MK, Pettersen S, Haugen MH, Olberg DE, Waaler J, Klaveness J (2019)
Towards dual inhibitors of the MET kinase and WNT signaling pathway; design, synthesis and biological evaluation
RSC Adv., 9 (63), 37092-37100

Lien VT, Pettersen S, Haugen MH, Olberg DE, Maelandsmo GM, Klaveness J (2019)
Design, synthesis and biological evaluation of 6-substituted quinolines derived from cabozantinib as c-Met inhibitors
Arch Pharm (Weinheim), 352 (9), e1900101
DOI 10.1002/ardp.201900101, PubMed 31414521

Lindholm EM, Ragle Aure M, Haugen MH, Kleivi Sahlberg K, Kristensen VN, Nebdal D, Børresen-Dale AL, Lingjaerde OC, Engebraaten O (2019)
miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
Mol Oncol, 13 (10), 2278-2296
DOI 10.1002/1878-0261.12561, PubMed 31402562

Lund-Andersen C, Nakken S, Nygård S, Fromm B, Aasheim LB, Davidson B, Julsrud L, Abrahamsen TW, Kristensen AT, Dybdahl B, Larsen SG, Hovig E, Flatmark K (2019)
Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response
Cold Spring Harb Mol Case Stud, 5 (2)
DOI 10.1101/mcs.a003566, PubMed 30862609

Mauseth B, Camilio KA, Shi J, Hammarström CL, Rekdal Ø, Sveinbjørnsson B, Line PD (2019)
The Novel Oncolytic Compound LTX-401 Induces Antitumor Immune Responses in Experimental Hepatocellular Carcinoma
Mol Ther Oncolytics, 14, 139-148
DOI 10.1016/j.omto.2019.05.002, PubMed 31211244

Meltzer S, Bakke KM, Rød KL, Negård A, Flatmark K, Solbakken AM, Kristensen AT, Fuglestad AJ, Kersten C, Dueland S, Seierstad T, Hole KH, Lyckander LG, Larsen FO, Schou JV, Patrick Brown D, Abrahamsson H, Redalen KR, Ree AH (2019)
Sex-related differences in primary metastatic site in rectal cancer; associated with hemodynamic factors?
Clin Transl Radiat Oncol, 21, 5-10
DOI 10.1016/j.ctro.2019.11.006, PubMed 31872084

Meltzer S, Bjørnetrø T, Lyckander LG, Flatmark K, Dueland S, Samiappan R, Johansen C, Kalanxhi E, Ree AH, Redalen KR (2019)
Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer
Transl Oncol, 12 (8), 1038-1044
DOI 10.1016/j.tranon.2019.04.014, PubMed 31146167

Menden MP, Wang D, Mason MJ, Szalai B, Bulusu KC, Guan Y, Yu T, Kang J, Jeon M, Wolfinger R, Nguyen T, Zaslavskiy M, AstraZeneca-Sanger Drug Combination DREAM Consortium, Jang IS, Ghazoui Z, Ahsen ME, Vogel R, Neto EC, Norman T, Tang EKY, Garnett MJ, Veroli GYD, Fawell S, Stolovitzky G, Guinney J et al. (2019)
Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen
Nat Commun, 10 (1), 2674
DOI 10.1038/s41467-019-09799-2, PubMed 31209238

Metcalfe K, Eisen A, Senter L, Armel S, Bordeleau L, Meschino WS, Pal T, Lynch HT, Tung NM, Kwong A, Ainsworth P, Karlan B, Moller P, Eng C, Weitzel JN, Sun P, Lubinski J, Narod SA, Hereditary Breast Cancer Clinical Study Group (2019)
International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation
Br J Cancer, 121 (1), 15-21
DOI 10.1038/s41416-019-0446-1, PubMed 30971774

Mingo J, Luna S, Gaafar A, Nunes-Xavier CE, Torices L, Mosteiro L, Ruiz R, Guerra I, Llarena R, Angulo JC, López JI, Pulido R (2019)
Precise definition of PTEN C-terminal epitopes and its implications in clinical oncology
NPJ Precis Oncol, 3, 11
DOI 10.1038/s41698-019-0083-4, PubMed 30993208

Møller P, Dominguez-Valentin M, Rødland EA, Hovig E (2019)
Causes for Frequent Pathogenic BRCA1 Variants Include Low Penetrance in Fertile Ages, Recurrent De-Novo Mutations and Genetic Drift
Cancers (Basel), 11 (2)
DOI 10.3390/cancers11020132, PubMed 30678073

Namløs HM, Boye K, Meza-Zepeda LA (2019)
Cell-free DNA in blood as a noninvasive insight into the sarcoma genome
Mol Aspects Med, 72, 100827
DOI 10.1016/j.mam.2019.10.004, PubMed 31703948

Nome ME, Euceda LR, Jabeen S, Debik J, Bathen TF, Giskeødegård GF, Taskén KA, Maelandsmo GM, Halvorsen B, Yndestad A, Borgen E, Garred Ø, Aukrust P, Ueland T, Engebraaten O, Kristensen VN, Tekpli X (2019)
Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers
Int J Cancer, 146 (1), 223-235
DOI 10.1002/ijc.32638, PubMed 31444972

Nunes-Xavier CE, Angulo JC, Pulido R, López JI (2019)
A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma
Curr Urol Rep, 20 (1), 1
DOI 10.1007/s11934-019-0866-8, PubMed 30645700

Nunes-Xavier CE, Aurtenetxe O, Zaldumbide L, López-Almaraz R, Erramuzpe A, Cortés JM, López JI, Pulido R (2019)
Protein tyrosine phosphatase PTPN1 modulates cell growth and associates with poor outcome in human neuroblastoma
Diagn Pathol, 14 (1), 134
DOI 10.1186/s13000-019-0919-9, PubMed 31837707

Nunes-Xavier CE, Zaldumbide L, Aurtenetxe O, López-Almaraz R, López JI, Pulido R (2019)
Dual-Specificity Phosphatases in Neuroblastoma Cell Growth and Differentiation
Int J Mol Sci, 20 (5)
DOI 10.3390/ijms20051170, PubMed 30866462

Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT, Brunsvig P, Yndestad A, Halvorsen B, Tasken KA, Aukrust P, Maelandsmo GM, Ueland T (2019)
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
Clin Exp Immunol, 197 (1), 74-82
DOI 10.1111/cei.13283, PubMed 30821848

Nygård S, Lingjærde OC, Caldas C, Hovig E, Børresen-Dale AL, Helland Å, Haakensen VD (2019)
PathTracer: High-sensitivity detection of differential pathway activity in tumours
Sci Rep, 9 (1), 16332
DOI 10.1038/s41598-019-52529-3, PubMed 31704995

Pandya AD, Jäger E, Bagheri Fam S, Höcherl A, Jäger A, Sincari V, Nyström B, Štěpánek P, Skotland T, Sandvig K, Hrubý M, Mælandsmo GM (2019)
Paclitaxel-loaded biodegradable ROS-sensitive nanoparticles for cancer therapy
Int J Nanomedicine, 14, 6269-6285
DOI 10.2147/IJN.S208938, PubMed 31496685

Pashov A, Shivarov V, Hadzhieva M, Kostov V, Ferdinandov D, Heintz KM, Pashova S, Todorova M, Vassilev T, Kieber-Emmons T, Meza-Zepeda LA, Hovig E (2019)
Diagnostic Profiling of the Human Public IgM Repertoire With Scalable Mimotope Libraries
Front Immunol, 10, 2796
DOI 10.3389/fimmu.2019.02796, PubMed 31849974

Pfefferle A, Jacobs B, Netskar H, Ask EH, Lorenz S, Clancy T, Goodridge JP, Sohlberg E, Malmberg KJ (2019)
Intra-lineage Plasticity and Functional Reprogramming Maintain Natural Killer Cell Repertoire Diversity
Cell Rep, 29 (8), 2284-2294.e4
DOI 10.1016/j.celrep.2019.10.058, PubMed 31747601

Pitman KE, Alluri SR, Kristian A, Aarnes EK, Lyng H, Riss PJ, Malinen E (2019)
Influx rate of 18F-fluoroaminosuberic acid reflects cystine/glutamate antiporter expression in tumour xenografts
Eur J Nucl Med Mol Imaging, 46 (10), 2190-2198
DOI 10.1007/s00259-019-04375-8, PubMed 31264167

Pitman KE, Bakke KM, Kristian A, Malinen E (2019)
Ultra-early changes in vascular parameters from dynamic contrast enhanced MRI of breast cancer xenografts following systemic therapy with doxorubicin and liver X receptor agonist
Cancer Imaging, 19 (1), 88
DOI 10.1186/s40644-019-0280-y, PubMed 31856923

Pulido R, Mingo J, Gaafar A, Nunes-Xavier CE, Luna S, Torices L, Angulo JC, López JI (2019)
Precise Immunodetection of PTEN Protein in Human Neoplasia
Cold Spring Harb Perspect Med, 9 (12)
DOI 10.1101/cshperspect.a036293, PubMed 31501265

Ree AH, Nygaard V, Russnes HG, Heinrich D, Nygaard V, Johansen C, Bergheim IR, Hovig E, Beiske K, Negård A, Børresen-Dale AL, Flatmark K, Mælandsmo GM (2019)
Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
Cancer Immunol Res, 7 (5), 701-706
DOI 10.1158/2326-6066.CIR-18-0777, PubMed 30804006

Saeednejad Zanjani L, Madjd Z, Rasti A, Asgari M, Abolhasani M, Tam KJ, Roudi R, Mælandsmo GM, Fodstad Ø, Andersson Y (2019)
Spheroid-Derived Cells From Renal Adenocarcinoma Have Low Telomerase Activity and High Stem-Like and Invasive Characteristics
Front Oncol, 9, 1302
DOI 10.3389/fonc.2019.01302, PubMed 31921617

Seppälä TT, Ahadova A, Dominguez-Valentin M, Macrae F, Evans DG, Therkildsen C, Sampson J, Scott R, Burn J, Möslein G, Bernstein I, Holinski-Feder E, Pylvänäinen K, Renkonen-Sinisalo L, Lepistö A, Lautrup CK, Lindblom A, Plazzer JP, Winship I, Tjandra D, Katz LH, Aretz S, Hüneburg R, Holzapfel S, Heinimann K et al. (2019)
Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report
Hered Cancer Clin Pract, 17, 8
DOI 10.1186/s13053-019-0106-8, PubMed 30858900

Shu X, Wu L, Khankari NK, Shu XO, Wang TJ, Michailidou K, Bolla MK, Wang Q, Dennis J, Milne RL, Schmidt MK, Pharoah PDP, Andrulis IL, Hunter DJ, Simard J, Easton DF, Zheng W, Breast Cancer Association Consortium (2019)
Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis
Int J Epidemiol, 48 (3), 795-806
DOI 10.1093/ije/dyy201, PubMed 30277539

Sneeggen M, Pedersen NM, Campsteijn C, Haugsten EM, Stenmark H, Schink KO (2019)
WDFY2 restrains matrix metalloproteinase secretion and cell invasion by controlling VAMP3-dependent recycling
Nat Commun, 10 (1), 2850
DOI 10.1038/s41467-019-10794-w, PubMed 31253801

Szybowska P, Kostas M, Wesche J, Wiedlocha A, Haugsten EM (2019)
Cancer Mutations in FGFR2 Prevent a Negative Feedback Loop Mediated by the ERK1/2 Pathway
Cells, 8 (6)
DOI 10.3390/cells8060518, PubMed 31146385

Sørensen O, Andersen AM, Larsen SG, Giercksky KE, Flatmark K (2019)
Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of high-grade pseudomyxoma peritonei
Clin Exp Metastasis, 36 (6), 511-518
DOI 10.1007/s10585-019-09991-0, PubMed 31541325

Tekpli X, Lien T, Røssevold AH, Nebdal D, Borgen E, Ohnstad HO, Kyte JA, Vallon-Christersson J, Fongaard M, Due EU, Svartdal LG, Sveli MAT, Garred Ø, OSBREAC, Frigessi A, Sahlberg KK, Sørlie T, Russnes HG, Naume B, Kristensen VN (2019)
An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment
Nat Commun, 10 (1), 5499
DOI 10.1038/s41467-019-13329-5, PubMed 31796750

Ten Broeke SW, Rodríguez-Girondo M, Suerink M, Aretz S, Bernstein I, Capellá G, Engel C, Gomez-Garcia EB, van Hest LP, von Knebel Doeberitz M, Lagerstedt-Robinson K, Letteboer TGW, Moller P, van Os TA, Pineda M, Rahner N, Olderode-Berends MJW, von Salomé J, Schackert HK, Spruijt L, Steinke-Lange V, Wagner A, Tops CMJ, Nielsen M (2019)
The Apparent Genetic Anticipation in PMS2-Associated Lynch Syndrome Families Is Explained by Birth-cohort Effect
Cancer Epidemiol Biomarkers Prev, 28 (6), 1010-1014
DOI 10.1158/1055-9965.EPI-18-0576, PubMed 30824524

Tolios A, De Las Rivas J, Hovig E, Trouillas P, Scorilas A, Mohr T (2019)
Computational approaches in cancer multidrug resistance research: Identification of potential biomarkers, drug targets and drug-target interactions
Drug Resist Updat, 48, 100662
DOI 10.1016/j.drup.2019.100662, PubMed 31927437

Webb M, Manley K, Olivan M, Guldvik I, Palczynska M, Hurst R, Connell SP, Mills IG, Brewer DS, Mills R, Cooper CS, Clark J (2019)
Methodology for the at-home collection of urine samples for prostate cancer detection
Biotechniques, 68 (2), 65-71
DOI 10.2144/btn-2019-0092, PubMed 31779479

Zakrzewska M, Opalinski L, Haugsten EM, Otlewski J, Wiedlocha A (2019)
Crosstalk between p38 and Erk 1/2 in Downregulation of FGF1-Induced Signaling
Int J Mol Sci, 20 (8)
DOI 10.3390/ijms20081826, PubMed 31013829

 
Page visits: 442351